Siren, L.L.C. Ascendis Pharma A/S Transaction History
Siren, L.L.C.
- $1.76 Trillion
- Q1 2025
A detailed history of Siren, L.L.C. transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Siren, L.L.C. holds 287,366 shares of ASND stock, worth $49.8 Million. This represents 2.55% of its overall portfolio holdings.
Number of Shares
287,366
Previous 297,321
3.35%
Holding current value
$49.8 Million
Previous $40.9 Billion
9.42%
% of portfolio
2.55%
Previous 1.81%
Shares
3 transactions
Others Institutions Holding ASND
# of Institutions
270Shares Held
61.9MCall Options Held
151KPut Options Held
226K-
Ra Capital Management, L.P. Boston, MA10.3MShares$1.78 Billion33.28% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.48MShares$949 Million4.42% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.22MShares$903 Million13.16% of portfolio
-
Janus Henderson Group PLC London, X04.49MShares$777 Million0.4% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.26MShares$737 Million1.14% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $9.66B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...